Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.bone.2013.12.025 http://scihub22266oqcxt.onion/10.1016/j.bone.2013.12.025 C3967551!3967551!24389365     free     free     free Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 263.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Bone 2014 ; 61 (ä): 39-43 Nephropedia Template TP {{tp|p=24389365|t=2014. PARATHYROID HORMONE RECEPTOR MEDIATES THE ANTI-MYELOMA EFFECT OF PROTEASOME INHIBITORS |pdf=|usr=}}{{24389365}} gab.com Text PARATHYROID HORMONE RECEPTOR MEDIATES THE ANTI-MYELOMA EFFECT OF PROTEASOME INHIBITORS JO: Bone http://www.kidney.de/pget.php?&tw=1&pmid=24389365 #FOAvip Clinically significant serum parathyroid hormone (PTH) variations have been reported in multiple myeloma (MM) patients treated with proteasome inhibitors. To elucidate the association between serum PTH variations and proteasome inhibition in MM, the effect of PTH and PTHR1 ligands on the proteasome inhibitors bortezomib and carfilzomib in vitro and in vivo was determined. The MM cell lines ARP1, OC1 and 5TGM1 expressed mRNA and protein encoding PTH receptor 1 (PTHR1). Treatment of 5TGM1 cells with either PTH(1?34), bortezomib or carfilzomib alone dose-dependently inhibited 5TGM1 cell proliferation. However, treatment with the potent PTHR1 antagonist [TYR34]PTH(7?34) (PTH(7?34)) had no significant effect on myeloma cell proliferation and cell viability. In contrast, when used in combination with bortezomib or carfilzomib, PTH(7?34) treatment significantly reduced the bortezomib or carfilzomib-associated decrease in cell proliferation. Treatment of the C57BL/KaLwRij mouse myeloma model with either bortezomib or carfilzomib provided a significantly prolonged survival benefit compared to controls (p=0.04; p=0.01 respectfully). This potent anti-myeloma effect was completely abrogated by concomitant treatment with PTH(7?34). These results suggest an important role of the PTHR1 in the anti-myeloma effect of proteosome inhibition. Twit Text FOAVip PARATHYROID HORMONE RECEPTOR MEDIATES THE ANTI-MYELOMA EFFECT OF PROTEASOME INHIBITORS ????Bone http://www.kidney.de/pget.php?&tw=1&pmid=24389365 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=24389365 #FOAvip English Wikipedia <ref>{{Cite pmid|24389365}}</ref> PARATHYROID HORMONE RECEPTOR MEDIATES THE ANTI-MYELOMA EFFECT OF PROTEASOME INHIBITORS #MMPMID24389365 Zangari M; Berno T; Yang Y; Zeng M; Xu H; Pappas L; Tricot G; Kamalakar A; Yoon D; Suva LJ Bone 2014[Apr]; 61 (ä): 39-43 PMID24389365show ga Clinically significant serum parathyroid hormone (PTH) variations have been reported in multiple myeloma (MM) patients treated with proteasome inhibitors. To elucidate the association between serum PTH variations and proteasome inhibition in MM, the effect of PTH and PTHR1 ligands on the proteasome inhibitors bortezomib and carfilzomib in vitro and in vivo was determined. The MM cell lines ARP1, OC1 and 5TGM1 expressed mRNA and protein encoding PTH receptor 1 (PTHR1). Treatment of 5TGM1 cells with either PTH(1?34), bortezomib or carfilzomib alone dose-dependently inhibited 5TGM1 cell proliferation. However, treatment with the potent PTHR1 antagonist [TYR34]PTH(7?34) (PTH(7?34)) had no significant effect on myeloma cell proliferation and cell viability. In contrast, when used in combination with bortezomib or carfilzomib, PTH(7?34) treatment significantly reduced the bortezomib or carfilzomib-associated decrease in cell proliferation. Treatment of the C57BL/KaLwRij mouse myeloma model with either bortezomib or carfilzomib provided a significantly prolonged survival benefit compared to controls (p=0.04; p=0.01 respectfully). This potent anti-myeloma effect was completely abrogated by concomitant treatment with PTH(7?34). These results suggest an important role of the PTHR1 in the anti-myeloma effect of proteosome inhibition. äPARATHYROID HORMONE RECEPTOR MEDIATES THE ANTI-MYELOMA EFFECT OF PROTE(epmc).pdf DeepDyve Pubget Overpricing